Search Results
Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress that Further Demonstrate Value of HDX Therapy Enabled by THERANOVA
Baxter International Inc. (NYSE: BAX), a global innovator in renal care, announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer clears large middle molecules at a higher rate when compared to standard hemodialysis (HD), and equivalent or higher removal rates compared to high-volume hemodiafiltration (HDF). Two studies presented also found that albumin levels remained stable during HDx treatment.
Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
Baxter International Inc. (NYSE: BAX), today at its investor conference, outlined the company’s strategies to drive sustained growth, deliver attractive shareholder value and advance patient care around the world. Baxter defined its top-quartile goals around four key areas: patient safety and quality; growth through innovation; best place to work; and industry-leading performance; and its leadership team highlighted strategic growth opportunities across its six global businesses.
Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease
Baxter International Inc. (NYSE:BAX), a global innovator in renal (kidney) care, and the International Society of Nephrology (ISN) announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) – commonly referenced as emerging markets – where the disease prevalence is growing the fastest.
Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018
Baxter International Inc. (NYSE: BAX) today reported results for the first quarter of 2018 and increased its full-year 2018 guidance.
Baxter Completes Acquistion of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
Baxter International Inc. (NYSE: BAX), a global medical products company, is committed to advancing surgical innovation and today announced it has completed its previously announced acquisition of two hemostat and sealant products from Mallinckrodt plc. RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.
Inspiring the Next Generation of Innovators
Impacting the lives of more than 1,000 students at Chicago charter school Muchin College Prep, Baxter’s Marc Minkus, senior director of program management, provided students with a first-hand account of how a STEM education opens the door to a rewarding career that can impact the lives of people around the world.
Paving the Way for Access to Critical Healthcare Needs
Baxter International Foundation Partners With Direct Relief to Rebuild Health Clinics in the Wake of Typhoon
Baxter Young Investigator Awards
Due to Baxter's planned spinoff of a new Kidney Care Company, the Baxter Young Investigator Awards program will pause for 2023 and return in 2024. We will reach out in the first quarter of 2024 with a call for applications that is aligned to the new organizational structure. Thank you for your interest.
University Partnerships
Our relationships with universities and institutes allow us to partner with leading innovators from around the world to bring together the best minds to understand unmet healthcare needs, generate new ideas and solve challenges.
